Biomay cGMP Contract Manufacturing of Plasmid DNA and Recombinant Proteins

Biomay is a Good Manufacturing Practice (GMP) contract development and manufacturing organisation (CDMO) for plasmid DNA and recombinant proteins (clinical phases I-III).

Headquartered in Vienna, Austria, Biomay has manufactured recombinant biomolecules with microbial systems (E. coli, yeasts) for more than 20 years.

Biomay has a particular track record in GMP manufacturing of advanced therapeutic medicinal products (ATMP) such as:

  • Plasmid DNA vectors for cell and gene therapies
  • Starting plasmids for viral vectors such as adeno-associated virus (AAV)
  • Non-viral DNA drug substances such as DNA-vaccines
  • Personalised, patient-specific DNA plasmids
  • Linearised DNA templates for in-vitro messenger ribonucleic acid (mRNA) transcription
  • Gene editing materials such as recombinant CRISPR-associated protein 9 (Cas9) nucleases

Scope of GMP contract services

Biomay offers the following GMP contract services:

  • Host / vector development
  • Current Good Manufacturing Practice (cGMP) cell banking (master and working cell banks)
  • Technology transfer and scale-up
  • Process development and optimisation
  • cGMP manufacturing of active pharmaceutical ingredients (API) / drug substance (plasmid DNA, recombinant proteins)
  • cGMP manual aseptic filling (drug product)
  • Quality control with well-established / validated assays
  • In-house Qualified Person (QP) release
  • Validation (assay / process / cleaning)
  • Storage and stability testing
  • Regulatory support such as Investigational Medicinal Product Dossier (IMPD) / Investigational New Drug (IND) applications

Plasmid DNA manufacturing

Biomay manufactures GMP-grade plasmid DNA (pDNA) for third party clients. As a plasmid CDMO, Biomay addresses clients requiring batch sizes ranging from 100mg to 20g.

Biomay´s plasmid DNA technology features:

  • High-yield E. coli hosts
  • High-cell density cultivation
  • Optimised culture media (no antibiotics or animal compounds)
  • Scalable alkaline lysis
  • High-performance downstream process (mainly single-use systems)
  • Highly homogenous pDNA (more than 90% supercoiled)

Biomay offers these quality levels for plasmid manufacturing:

  • Full GMP/cGMP for drug substances and critical start materials
  • High-quality for DNA transcription templates and pre-clinical materials
  • Research and development (R&D) for research purposes

GMP facility and manufacturing capacities

Biomay`s GMP facility consists of following areas:

  • Cleanroom class D (upstream / midstream processing)
  • Cleanroom class C (downstream processing)
  • Cleanroom class A/B (unidirectional airflow units for aseptic filling)
  • Airlocks for personnel and material flow
  • State-of-the-art heat ventilation and air conditioning (HVAC)
  • Preparation, service and storage areas
  • Quality control laboratories

Processing equipment and techniques

The complete processing chain for microbial biopharmaceuticals is established. Biomay caters to:

Upstream

  • Rotary shakers
  • Bioreactors: 5l / 25l / 45l
  • Fed-batch fermentation / high cell density cultivation

Midstream:

  • Batch or continuous flow centrifuges
  • High-pressure homogenisers
  • Alkaline cell lysis
  • Protein refolding

Downstream (purification):

  • Process chromatographies (pilot-scale, up to ~20g drug substance/batch)
  • Chromatographic techniques: capillary electrochromatography (CEC), anion-exchange chromatography (AEC), hydrophobic interaction chromatography (HIC), immobilised metal affinity chromatography (IMAC) and affinity chromatography (AC)
  • Filtration techniques such as depth, ultrafiltration (UF) / depth filter (DF)

Filling and finishing (partially with subcontracting partners):

  • Aseptic 0.2µm filtration
  • Manual aseptic filling / class A

Analytical services and quality control

Analytical testing and in-process controls conforming with United States Pharmacopoeia (USP) / European Pharmacopoeia (PhEur) standards are offered. Assay development, validation and stability testing can be performed. Biomay employs a certified QP for internal drug product release.

Established analytical methods:

  • Electrophoresis: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), Western blot, Agarose gel electrophoresis (AGE)
  • High-performance liquid chromatography (HPLC), including reversed-phase (RP), ion-exchange chromatography (IEC), and size-exclusion chromatography (SEC) varieties
  • Spectroscopies: ultraviolet (UV), optical density (OD) 600, mass spectrometry (MS), circular dichroism (CD) and dynamic light scattering (DSC)
  • Immunochemical: Enzyme-linked immunosorbent assay (ELISA), (product-specific, host cell protein, host cell DNA)
  • Microbiological: bioburden, viability, phenotypic identification, plasmid retention, bacteriophages
  • Other methods: peptide / restriction mapping, DNA / protein sequencing, amino acid composition, endotoxins, total organic carbon (TOC).

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Address
Biomay AG

Vienna Competence Center

Lazarettgasse 19


1090 Vienna


Austria

+43 79 662 96100
 +43 796 629 6111 www.biomay.com

Biomay Images

Products and Services

Video

White Papers

Related Projects



Press Release

Regional Offices

Biomay AG

Vienna Competence Center

Lazarettgasse 19


1090 Vienna


Austria

+43 79 662 96100
 +43 796 629 6111 www.biomay.com

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.